This content material initially appeared on Beyond Type 1. Republished with permission.
By Lala Jackson
On March 22, 2021, Zealand Pharma announced the FDA approval of Zegalogue in an autoinjector and prefilled syringe. The approval will add two extra easy-to-use glucagon choices, becoming a member of Eli Lilly’s nasal glucagon Baqsimi and Xeris Prescribed drugs’ GVOKE HypoPen and prefilled syringe.
Slated to be commercially accessible within the US in June 2021 for ages six and older, Zegalogue’s approval follows three scientific trials in adults and kids with insulin-dependent diabetes. Following use of Zegalogue in response to extreme hypoglycemia, sufferers confirmed restoration (a rise in blood glucose of ≥ 20 mg/dL) inside 10-Quarter-hour.
Dasiglucagon is a peptide analog (i.e. a human-created drug designed to imitate the precise hormone) model of glucagon, a naturally occurring hormone that triggers the physique to launch glucose reserves from the liver to boost blood sugar. Within the physique of an individual with diabetes, this course of needs to be manually managed. Nonetheless, partly as a result of easy-to-use glucagon options are pretty new to the market, many individuals with insulin-dependent diabetes don’t sometimes carry or know when to make use of glucagon.
FDA steering for Zegalogue and different types of glucagon point out utilization in response to any extreme hypoglycemic occasion, outlined as a extreme low blood sugar throughout which the particular person experiencing the low turns into unable to simply assist themselves. An individual with diabetes doesn’t should be experiencing seizures or unconsciousness earlier than dosing glucagon, and it’s safer to dose glucagon earlier than both happens.
For all types of glucagon, possible side effects after dosing are nausea, vomiting, and headache, with a small variety of individuals additionally experiencing diarrhea or injection web site ache.